PharmX Technologies (ASX:PHX) YoY EBITDA Growth: -200.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is PharmX Technologies YoY EBITDA Growth?

PharmX Technologies ASX:PHX -4.65% YoY EBITDA Growth is -200.00% as of Jun. 2026.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. PharmX Technologies's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -200.00%.

PharmX Technologies's EBITDA per Share for the six months ended in Jun. 2026 was A$-0.00.

PharmX Technologies YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies YoY EBITDA Growth Chart

PharmX Technologies Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.33 -75.00 100.00 0.00 -100.00

PharmX Technologies Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -50.00 -200.00

PharmX Technologies YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

PharmX Technologies's YoY EBITDA Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (A: Jun. 2026 )
=(EBITDA per Share (A: Jun. 2026 )-EBITDA per Share (A: Jun. 2025 ))/ | EBITDA per Share (A: Jun. 2025 ) |
=(-0-0.002)/ | 0.002 |
=-100.00 %

PharmX Technologies's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.001-0.001)/ | 0.001 |
=-200.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -200.00% mean?
PharmX Technologies (ASX:PHX) has a YoY EBITDA Growth of -200.00% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for PharmX Technologies and its competitors.
Is PharmX Technologies' YoY EBITDA Growth too high?
PharmX Technologies' current YoY EBITDA Growth is -200.00%.
How does PharmX Technologies' YoY EBITDA Growth compare to VEEV and BTSG?
PharmX Technologies' YoY EBITDA Growth of -200.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for PharmX Technologies and its competitors. PharmX Technologies's current YoY EBITDA Growth is -200.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Fairly Valued. The stock's GF Value™ is A$0.08, compared to a current price of A$0.08 — trading 2.5% above its estimated fair value. The current YoY EBITDA Growth is -200.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current YoY EBITDA Growth is -200.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.